THERIVA BIOLOGICS INC (TOVX)
NYSE MKTHealth CareBiotechnologySnapshot 2026-09-04
$0.250.00%
Close 2026-09-04 · 1-day change
NYSE MKTHealth CareBiotechnologySnapshot 2026-09-04
Broken: Primary pillar broken — Manage operating losses: metric not reported.
Theriva Biologics has secured an exclusive worldwide license with Rasayana Therapeutics, which could drive future growth. The company has shown some earnings beats recently, indicating potential progress. Management is focused on managing operating losses, which have decreased from $4.44 million to $2.13 million. These steps suggest a path toward stabilizing the business.
Theriva Biologics remains loss-making with negative earnings expected through 2027. The company faces ongoing litigation and has no current revenue guidance. Operating losses persist, and recent share price has dropped over 40% from its high. These challenges could delay or prevent a turnaround.
The market is selling off the stock sharply, reflecting skepticism about near-term profitability and growth. There is no clear consensus revenue or earnings growth priced in, and the company’s losses and litigation risks weigh on sentiment. Our view sees some potential from the license deal but acknowledges the high risk.
Breaks if: EPS loss remains at or below -$0.20 by FY27
Breaks if: no material progress or revenue from Rasayana license by FY27
Breaks if: operating loss remains above $2 million next 4 quarters
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity in the healthcare sector. The current thesis state is cautious, with management focused on advancing clinical trials while navigating recent financial performance issues.
The market appears to have low expectations for TOVX, as indicated by its alignment with peers despite being loss-making. There is a medium level of confidence in the valuation model, suggesting that current valuations reflect a cautious outlook.
Fundamentals may remain neutral in the near term, given the company's recent earnings miss and the high probability of missing future estimates. Management's focus on advancing clinical trials could provide some positive momentum if successful.
The thesis hinges on several factors, including the outcomes of ongoing clinical trials and the overall performance of the healthcare sector. Additionally, any guidance cuts or worsening economic indicators could negatively impact sentiment.
In the next 1 to 3 years, TOVX's performance will depend heavily on clinical trial advancements and sector dynamics. Not investment advice.
The most important moves since the prior daily snapshot.
No, our read on the company is unchanged. There are no new strengths or weaknesses identified. Recent financial performance remains steady, but it is worth watching. The company continues to be unprofitable, which limits assessment of its quality.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.